Active	Status	Sponsor type	Region	Phase	Filter
5 Active 2 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Blank, Stephen C
NCT05303636: LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women	Recruiting	4	1710	US	LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet	Insud Pharma, Chemo Research	Change in Bone Mineral Density, Bone Loss	07/26	03/27
NCT05264506: Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive	Terminated	3	2007	US	NOMAC-E2 COC, Nomegestrol acetate / estradiol	Organon and Co, IQVIA Inc., OSTAtistics	Contraception	01/24	01/24
NCT05399641: Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis	Completed	3	150	US	Ibrexafungerp	Scynexis, Inc.	Vulvovaginal Candidiasis	05/23	08/23
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH	Active, not recruiting	2	271	Europe, Canada, Japan, US, RoW	GSK4532990, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease	12/25	03/26